Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
September 30, 2026 -3.078M
June 30, 2026 -6.54M
March 31, 2026 -8.023M
December 31, 2025 -7.156M
September 30, 2025 -9.732M
June 30, 2025 -9.597M
March 31, 2025 -13.36M
December 31, 2024 -14.43M
September 30, 2024 -13.97M
June 30, 2024 -16.14M
March 31, 2024 -16.75M
December 31, 2023 -14.26M
September 30, 2023 -16.75M
June 30, 2023 -15.11M
Date Value
March 31, 2023 -23.40M
December 31, 2022 -17.95M
September 30, 2022 -13.45M
June 30, 2022 -20.79M
March 31, 2022 -24.31M
December 31, 2021 -17.79M
September 30, 2021 -18.73M
June 30, 2021 -3.986M
March 31, 2021 -16.56M
December 31, 2020 -12.89M
September 30, 2020 -12.52M
June 30, 2020 -12.26M
March 31, 2020 -9.638M
December 31, 2019 -6.262M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Caribou Biosciences, Inc. -22.52M
Oncolytics Biotech, Inc. -6.754M
Sangamo Therapeutics, Inc. -19.28M
Sarepta Therapeutics, Inc. 59.97M
Anixa Biosciences, Inc. -1.77M